A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
about
Neurodegeneration in multiple sclerosis: novel treatment strategiesNew and emerging disease modifying therapies for multiple sclerosisN-Acetylglucosamine Inhibits T-helper 1 (Th1)/T-helper 17 (Th17) Cell Responses and Treats Experimental Autoimmune EncephalomyelitisCurrent Concepts in Multiple Sclerosis: Autoimmunity Versus OligodendrogliopathyMultiple Sclerosis: Where Will We Be in 2020?Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approachTreatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosisAdverse effects of immunotherapies for multiple sclerosis: a network meta-analysisIdentification of targets and new developments in the treatment of multiple sclerosis--focus on cladribineThe challenge of comorbidity in clinical trials for multiple sclerosisRelating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysisPharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisMultiple sclerosis: the role of cytokines in pathogenesis and in therapiesDiagnosis and Management of Multiple Sclerosis in ChildrenNo evidence for higher risk of cancer in patients with multiple sclerosis taking cladribineCladribine tablets for the treatment of relapsing-remitting multiple sclerosisClarity and strength of implications for practice in medical journal articles: an exploratory analysisDevelopment of oral immunomodulatory agents in the management of multiple sclerosisEstablishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MSCladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear CellsPlacebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case dataUsing historical control information for the design and analysis of clinical trials with overdispersed count data.A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis.Brain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact.Assessing changes in relapse rates in multiple sclerosis.Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisCladribine tablets: in relapsing-remitting multiple sclerosis.3,3'-diindolylmethane ameliorates experimental autoimmune encephalomyelitis by promoting cell cycle arrest and apoptosis in activated T cells through microRNA signaling pathways.Clinical characteristics of multiple sclerosis in Kuwait: data from the new MS registry of Amiri Hospital.Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study.Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tabletsUse of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ).Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosisToxicities of immunosuppressive treatment of autoimmune neurologic diseases.New approaches in the management of multiple sclerosis.Therapeutic strategies in childhood multiple sclerosisChemotherapeutics in the treatment of multiple sclerosis.Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice.
P2860
Q22241472-738F1BCC-CE45-4FD2-90A2-067148B3C2C8Q22242305-963A0558-B9ED-414A-86E4-56A3BE959965Q22248070-049A2ACD-7FD2-4F32-B4A6-BE4E0F22F144Q22252578-219CDB7C-E752-493C-9D14-AF0A36858306Q22252863-BE410CA5-76B8-4076-9161-0C609C8C9D8BQ22305854-EBAC1D3C-2A77-4B55-9475-51776DE7BB82Q24185806-AB9BD6F8-3E4A-4C75-B51C-C3A3C756DD36Q24185820-EEE29E0A-889A-450D-BDF9-E43C4B93F6B3Q24597369-B6A8067F-84AD-4740-A58B-D9159A868403Q26765031-79151D11-A08F-41B9-B08D-7A747FD9B93CQ26828463-1EE22047-F1D4-42C6-BE53-FC0D6FE73B19Q27000269-37BFA153-2D0A-4065-8FB4-A2D4B0F8DB29Q27011014-4AB8B18C-A872-40C9-B345-708CBEA44681Q28069571-D662120F-6694-4EA0-9DC5-8F1EB2666D11Q28268596-E48A3EA0-917B-46A1-89ED-3CE5821B7178Q28281816-0DE817EC-9FAD-4B0D-BC60-DCCBEC0862F3Q28387287-7EDDC1CD-AF1F-4AA0-8FBE-8DD21D96A639Q28388704-8EF3EE58-A9FA-4A52-82E0-8EB20CE2B223Q28478190-EAA464D8-101F-4126-9C92-921B6D3FD2A8Q28548449-B2B3FC9A-C502-4E8F-BB9A-33F656CC853EQ30000824-3F0BE493-3D4A-4991-A66C-24519B73B6ACQ30636643-BB3D440D-3C5B-473C-BD01-457671F52E36Q30716854-22147720-801F-42CC-8444-3237EA93ACF3Q31070072-074D91C3-AE3B-416C-9076-80EDF422F177Q33681680-18E0324F-9066-42E4-A01B-F7CBD377CF60Q33777872-5BC5CA03-7746-47AB-BDA3-F7B63CF0F333Q33802186-E67CD563-0CFD-4826-A720-25405BBC7DA4Q33821160-1E19CFC8-1BF5-421A-A3B7-41A7DC2FED06Q33944014-2F4F8F4D-EEC7-49A2-B35D-5A9998983419Q34045441-36B98D24-C426-4495-9468-1AA034E05549Q34053766-CCC4EA3E-141B-4771-99B9-CC0CDC0947E2Q34100842-0EFBB6DE-4BCA-4642-B4E2-26F9E8DEF16AQ34133316-A2D6C6FE-B8E1-4946-9CB7-F642C77BC3CFQ34160752-E5320DEB-EB6F-43FD-A750-3E9BA65F3765Q34184148-8721C735-E23D-4B77-ACD8-D4367DB94695Q34257903-68A4AACA-5D85-4673-92E7-7540E8298E4AQ34389528-84E3B955-9E75-45BB-AF07-06947188B090Q34409508-A4F2AE3F-8DAB-440E-B008-4C991C6E9763Q34409536-2FE103D8-330A-40D3-B00E-ADDECEE0C6EEQ34441015-E546D19E-3C1A-4C52-AD5A-B503C45780CD
P2860
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
@ast
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
@en
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
@nl
type
label
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
@ast
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
@en
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
@nl
prefLabel
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
@ast
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
@en
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
@nl
P2093
P50
P356
P1476
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
@en
P2093
Anthony Hamlett
Bruno Musch
CLARITY Study Group
Kottil Rammohan
Patrick Vermersch
Peter Chang
Peter Rieckmann
Steven J Greenberg
Stuart Cook
P304
P356
10.1056/NEJMOA0902533
P407
P577
2010-01-20T00:00:00Z